MiMedx Group (MDXG) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharming Group N.V. (PHAR) has outperformed MiMedx Group (MDXG) over the past year, losing 34.2% versus a loss of 36.5%. Over five years, PHAR leads with a +2.2% price change compared with -31.8% for MDXG. Pharming Group N.V. is the larger company by market cap ($674.5 million vs $671.3 million), about 1.0 times the size.
On valuation, MiMedx Group trades at a lower forward P/E (23.0x vs 31.0x for Pharming Group N.V.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | PHAR |
|---|---|---|
| Share price | $4.60 | $9.53 |
| Market cap | $671.30M | $674.52M |
| 1-day change | -0.22% | -1.24% |
| YTD return | -31.91% | -45.39% |
| 1-year return | -36.50% | -34.22% |
| 5-year return | -31.80% | +2.22% |
| P/E ratio (TTM) | 115.00 | 73.31 |
| Forward P/E | 23.00 | 31.04 |
| EPS (TTM) | $0.04 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $21.34 |
| 52-week low | $3.03 | $9.44 |
| Distance from 52-week high | -42.28% | -55.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +60.87% | +260.44% |
| Average volume | 1.23M | 22.82K |
| Shares outstanding | 145.93M | 70.78M |
| Employees | 808 | 407 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MiMedx Group trades at a higher earnings multiple (115.0x vs 73.3x trailing P/E).
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
MDXG vs PHAR FAQ
Which is bigger, MiMedx Group or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $674.52M compared with $671.30M for MiMedx Group (MDXG).
Which stock has performed better over the past year, MDXG or PHAR?
PHAR returned -34.22% over the past 12 months, compared with -36.50% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MDXG or PHAR?
PHAR has the lower trailing P/E at 73.3, versus 115.0 for MDXG. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are MiMedx Group and Pharming Group N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for MiMedx Group and Biotechnology: Pharmaceutical Preparations for Pharming Group N.V..